Doris Hansen

Hematology | Oncology

12902 Usf Magnolia Dr
Tampa, FL 33612

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 101 publications

Correction: Safety and efficacy of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: a CIBMTR study.

Correction: Safety and efficacy of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: a CIBMTR study.

Journal: Blood cancer journal

Published: August 31, 2026

Prognostic factors for patients with relapsed or refractory multiple myeloma who are initiating a fourth or later line car T-cell or bispecific antibody therapy: a systematic literature review and meta-analysis.

Prognostic factors for patients with relapsed or refractory multiple myeloma who are initiating a fourth or later line car T-cell or bispecific antibody therapy: a systematic literature review and meta-analysis.

Journal: Expert review of hematology

Published: June 10, 2026

Prognostic factors for patients with relapsed or refractory multiple myeloma who are initiating a fourth or later line car T-cell or bispecific antibody therapy: a systematic literature review and meta-analysis.

Prognostic factors for patients with relapsed or refractory multiple myeloma who are initiating a fourth or later line car T-cell or bispecific antibody therapy: a systematic literature review and meta-analysis.

Journal: Expert review of hematology

Published: June 10, 2026

Clinical outcomes with ciltacabtagene autoleucel among patients with relapsed/refractory multiple myeloma after four or more prior lines of therapy overall and among subgroups based on age, frailty, and CRAB symptoms.

Clinical outcomes with ciltacabtagene autoleucel among patients with relapsed/refractory multiple myeloma after four or more prior lines of therapy overall and among subgroups based on age, frailty, and CRAB symptoms.

Journal: Current medical research and opinion

Published: April 30, 2026

Real-world outcomes with BCMA- and GPRC5D-targeting bispecific antibodies in plasma cell leukemia.

Real-world outcomes with BCMA- and GPRC5D-targeting bispecific antibodies in plasma cell leukemia.

Journal: Blood advances

Published: April 21, 2026

Real-World Outcomes with BCMA- and GPRC5D-Targeting Bispecific Antibodies in Plasma Cell Leukemia.

Real-World Outcomes with BCMA- and GPRC5D-Targeting Bispecific Antibodies in Plasma Cell Leukemia.

Journal: Blood advances

Published: April 21, 2026

Exercise Prehabilitation for Older Adults Undergoing CAR-T: Feasibility, Acceptability, and Preliminary Outcomes.

Exercise Prehabilitation for Older Adults Undergoing CAR-T: Feasibility, Acceptability, and Preliminary Outcomes.

Journal: Transplantation and cellular therapy

Published: April 15, 2026

Exercise Prehabilitation for Older Adults Undergoing CAR-T: Feasibility, Acceptability, and Preliminary Outcomes.

Exercise Prehabilitation for Older Adults Undergoing CAR-T: Feasibility, Acceptability, and Preliminary Outcomes.

Journal: Transplantation and cellular therapy

Published: April 15, 2026

Real-World Incidence and Management of Non-Immune Effector Cell-Associated Neurotoxicity Syndrome Neurologic Events Following Ciltacabtagene Autoleucel in Multiple Myeloma.

Real-World Incidence and Management of Non-Immune Effector Cell-Associated Neurotoxicity Syndrome Neurologic Events Following Ciltacabtagene Autoleucel in Multiple Myeloma.

Journal: Clinical epidemiology

Published: April 10, 2026

Chronic graft vs. host disease following post-transplant cyclophosphamide (PTCy) based prophylaxis vs. non-PTCy prophylaxis.

Chronic graft vs. host disease following post-transplant cyclophosphamide (PTCy) based prophylaxis vs. non-PTCy prophylaxis.

Journal: Blood advances

Published: April 08, 2026

Condensed vs. Standard Step-Up Dosing Schedule of Talquetamab in Relapsed/Refractory Multiple Myeloma.

Condensed vs. Standard Step-Up Dosing Schedule of Talquetamab in Relapsed/Refractory Multiple Myeloma.

Journal: European journal of haematology

Published: April 02, 2026

BIO26-048: A Meta-Analytic Evaluation of Efficacy and Safety Between Ide-cel and Cilta-cel in Relapsed/Refractory Multiple Myeloma Based on Clinical Trial and Real-World Data.

BIO26-048: A Meta-Analytic Evaluation of Efficacy and Safety Between Ide-cel and Cilta-cel in Relapsed/Refractory Multiple Myeloma Based on Clinical Trial and Real-World Data.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: March 31, 2026

Showing 1-12 of 101

Last Updated: 09/26/2026